XML 35 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 02, 2021
USD ($)
$ / shares
shares
May 13, 2021
USD ($)
Jul. 23, 2018
USD ($)
Oct. 19, 2017
USD ($)
Oct. 31, 2015
Sep. 30, 2022
USD ($)
agreement
$ / shares
shares
Sep. 30, 2021
$ / shares
shares
Sep. 30, 2022
USD ($)
agreement
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Significant Accounting Policies [Line Items]                  
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares           $ 0.001 $ 0.001 $ 0.001 $ 0.001
Stock issuance proceeds               $ 4,161 $ 8,575
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares           33,922,624 27,962,842 33,295,154 26,847,081
2021 Notes                  
Significant Accounting Policies [Line Items]                  
Interest rate (as a percent)             7.50%   7.50%
2024 Notes                  
Significant Accounting Policies [Line Items]                  
Interest rate (as a percent)           7.50%   7.50%  
Maintain of Minimum Cash Balance           $ 7,500   $ 7,500  
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil                  
Significant Accounting Policies [Line Items]                  
Collaborative Arrangement Revenues Expenses Sharing Percentage         100.00%        
Chiesi US Agreement and Chiesi Ex-US Agreement                  
Significant Accounting Policies [Line Items]                  
Non-refundable Payment Receivable     $ 25,000 $ 25,000          
Chiesi Agreements                  
Significant Accounting Policies [Line Items]                  
Performance obligation number | agreement           2   2  
Chiesi US Agreement                  
Significant Accounting Policies [Line Items]                  
Additional Amounts Payable To Cover Development Costs     20,000            
Maximum entitlement of development costs to cover per year     7,500            
Additional amount payable for achievement of regulatory and commercial milestones     $ 760,000            
Chiesi US Agreement | Minimum                  
Significant Accounting Policies [Line Items]                  
Payment On Net Sales Percentage     15.00%            
Chiesi US Agreement | Maximum                  
Significant Accounting Policies [Line Items]                  
Payment On Net Sales Percentage     40.00%            
Chiesi Ex-US Agreement                  
Significant Accounting Policies [Line Items]                  
Additional Amounts Payable To Cover Development Costs       25,000          
Maximum entitlement of development costs to cover per year       10,000          
Additional amount payable for achievement of regulatory and commercial milestones       $ 320,000          
Change in amount receivable for achievement of regulatory and commercial milestones   $ 25,000              
Agreement Amendment Payment Receivable   $ 10,000              
Chiesi Ex-US Agreement | Minimum                  
Significant Accounting Policies [Line Items]                  
Payment On Net Sales Percentage       15.00%          
Chiesi Ex-US Agreement | Maximum                  
Significant Accounting Policies [Line Items]                  
Payment On Net Sales Percentage       35.00%          
ATM Shares                  
Significant Accounting Policies [Line Items]                  
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares $ 0.001                
Sale of stock, maximum offering price $ 20,000             $ 15,600  
Number of shares issued (in shares) | shares 3,296,123                
Stock issuance proceeds $ 13,800